Xintela decreases patient number in XSTEM clinical study in difficult-to-heal venous leg ulcers
Xintela has amended the study protocol in the clinical phase I/IIa study with XSTEM on patients with difficult-to-heal venous leg ulcers to complete the study earlier. The number of patients to be enrolled in the study has been reduced from 12 to 6. The primary goal of the study, to investigate safety and tolerability, will […]
Xintela’s stem cell product XSTEM shows safety and positive efficacy results in knee osteoarthritis clinical study
Xintela’s interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically significant and clinically meaningful improvements in knee pain and knee function. In addition, the results of XSTEM treatment show an improvement in bone structure and also a trend […]
Xintela AB Year-end Report 2024
Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2024Income amounted to TSEK 1,090 (78).Loss before tax totalled TSEK 11,712 (loss: 12,175).Loss per share* was SEK 0.02 (loss: 0.03). Full year 2024Income amounted to TSEK 4,215 (78).Loss before tax totalled TSEK 41,534 (loss: 58,367).Loss […]
Xintelling No. 5 2024
Read Xintela´s newsletter in English here. Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]
Xintela AB Interim Report January – September 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupThird quarter 2024Income amounted to TSEK 2,822 (0).Loss before tax totalled TSEK 8,049 (loss: 11,953).Loss per share was SEK 0.01 (loss: 0.02). First nine month 2024Income amounted to TSEK 3,125 (0).Loss before tax totalled TSEK 29,821 (loss: 46,192).Loss […]
Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million
Xintela AB (publ) (“Xintela” or the “Company”) today announces that the Company’s largest shareholder Flerie Invest AB, which holds approximately 55.5 percent of the number of shares and votes in the Company, has committed to exercise warrants of series TO3 of approximately SEK 28 million during the exercise period beginning on November 25, 2024. Flerie’s […]
Xintelling, No. 4 2024
Read Xintela´s newsletter in English here. Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]
Xintela presents new preclinical results of XSTEM treatment on would healing and skin regeneration at cell therapy conference
Xintela is presenting today new preclinical data with the company’s stem cell product XSTEM® for wound healing and skin regeneration at the International Society for Cell & Gene Therapy (ISCT) Europe 2024, in Gothenburg. The results are presented both as a poster and as an oral presentation. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected […]
Xintela AB Interim Report January – June 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. THE GROUPSecond quarter 2024Income amounted to TSEK 4 (0).Loss before tax totalled TSEK 10,400 (loss: 18,401).Loss per share was SEK 0.02 (loss: 0.06). First half year 2024Income amounted to TSEK 303 (0).Loss before tax totalled TSEK 21,773 (loss: 34,244).Loss […]
Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients
Xintela and Region Östergötland have signed an agreement where Xintela will develop and establish a GMP process to isolate and quality assure autologous (patient-own) skin cells for the treatment of burns. The agreement is worth SEK 3.6 million. The process will form the basis for an approval from the Medical Products Agency for the Burn […]
